Department of Neurology, Center for Circadian and Sleep Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
J Clin Sleep Med. 2020 Dec 15;16(12):2047-2062. doi: 10.5664/jcsm.8750.
The purpose of this study was to evaluate the feasibility and acceptability of a novel cognitive behavioral therapy for hypersomnia (CBT-H) in people with central disorders of hypersomnolence and co-occurring depressive symptoms using a telehealth model for delivery and assessment.
Thirty-five adults with narcolepsy or idiopathic hypersomnia received a 6-session CBT-H delivered individually or in small groups using videoconferencing. The clinical impact of CBT-H was evaluated using the Patient Health Questionnaire, Patient-Reported Outcomes Measurement Information System measures, Epworth Sleepiness Scale, and other patient-reported outcomes collected online at baseline and posttreatment. Feasibility and acceptability of the intervention and telehealth model was also evaluated using qualitative data collected from exit interviews conducted through videoconferencing.
Forty percent of the sample achieved a clinically significant baseline to posttreatment change in depressive symptoms (decrease in Patient Health Questionnaire ≥ 5), which is below the prespecified efficacy benchmark (50% of the sample). The prespecified benchmark for a minimal clinically important difference (Cohen's d > 0.5) on other psychosocial measures was met only on the Patient-Reported Outcomes Measurement Information System global self-efficacy (d = 0.62) in the total sample. Qualitative data revealed enthusiasm for the accessibility of telehealth delivery and the usefulness of several cognitive and behavioral modules but also revealed opportunities to refine the CBT-H program.
These findings indicate that this new CBT-H program can potentially reduce depressive symptoms and improve self-efficacy in people with central disorders of hypersomnolence. Furthermore, telehealth is a promising model for remote delivery and data collection to enhance participant accessibility and engagement.
Registry: ClinicalTrials.gov; Name: Psychosocial Adjunctive Treatment for Hypersomnia (PATH); URL: https://clinicaltrials.gov/ct2/show/NCT03904238; Identifier: NCT03904238.
本研究旨在评估使用远程医疗模式进行个体化或小团体授课的新型针对嗜睡症的认知行为疗法(CBT-H)在伴有共病抑郁症状的中枢性嗜睡障碍患者中的可行性和可接受性。
35 名患有发作性睡病或特发性嗜睡症的成年人接受了 6 次个体或小团体的认知行为疗法(CBT-H)。通过问卷调查的方式评估 CBT-H 的临床影响,评估工具包括患者健康问卷、患者报告的结局测量信息系统量表、Epworth 嗜睡量表以及基线和治疗后在线收集的其他患者报告结局。通过视频会议进行的退出访谈收集的定性数据也评估了干预措施和远程医疗模式的可行性和可接受性。
40%的样本在抑郁症状方面达到了临床显著的基线至治疗后变化(患者健康问卷评分下降≥5),这低于预设的疗效基准(样本的 50%)。其他心理社会测量的最小临床重要差异(Cohen's d > 0.5)的预设基准仅在总样本的患者报告的结局测量信息系统总体自我效能(d = 0.62)上得到满足。定性数据显示,远程医疗的可及性和认知行为模块的有用性得到了参与者的认可,但也为改进 CBT-H 方案提供了机会。
这些发现表明,这种新的针对嗜睡症的认知行为疗法方案可能会减少中枢性嗜睡障碍患者的抑郁症状,并提高自我效能感。此外,远程医疗是一种很有前途的远程提供和数据收集模式,可以提高参与者的可及性和参与度。
注册机构:ClinicalTrials.gov;名称:嗜睡症的心理社会辅助治疗(PATH);网址:https://clinicaltrials.gov/ct2/show/NCT03904238;标识符:NCT03904238。